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Eﬀ ects of extended-release metoprolol succinate in patients 
undergoing non-cardiac surgery (POISE trial): a randomised 
controlled trial
POISE Study Group*
Summary
Background Trials of β blockers in patients undergoing non-cardiac surgery have reported conﬂ icting results. This 
randomised controlled trial, done in 190 hospitals in 23 countries, was designed to investigate the eﬀ ects of 
perioperative β blockers.
Methods We randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing 
non-cardiac surgery to receive extended-release metoprolol succinate (n=4174) or placebo (n=4177), by a computerised 
randomisation phone service. Study treatment was started 2–4 h before surgery and continued for 30 days. Patients, 
health-care providers, data collectors, and outcome adjudicators were masked to treatment allocation. The primary 
endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal cardiac arrest. 
Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00182039.
Findings All 8351 patients were included in analyses; 8331 (99·8%) patients completed the 30-day follow-up. Fewer 
patients in the metoprolol group than in the placebo group reached the primary endpoint (244 [5·8%] patients in the 
metoprolol group vs 290 [6·9%] in the placebo group; hazard ratio 0·84, 95% CI 0·70–0·99; p=0·0399). Fewer patients 
in the metoprolol group than in the placebo group had a myocardial infarction (176 [4·2%] vs 239 [5·7%] patients; 
0·73, 0·60–0·89; p=0·0017). However, there were more deaths in the metoprolol group than in the placebo group 
(129 [3·1%] vs 97 [2·3%] patients; 1·33, 1·03–1·74; p=0·0317). More patients in the metoprolol group than in the 
placebo group had a stroke (41 [1·0%] vs 19 [0·5%] patients; 2·17, 1·26–3·74; p=0·0053).
Interpretation Our results highlight the risk in assuming a perioperative β-blocker regimen has beneﬁ t without 
substantial harm, and the importance and need for large randomised trials in the perioperative setting. Patients are 
unlikely to accept the risks associated with perioperative extended-release metoprolol. 
Funding Canadian Institutes of Health Research; Commonwealth Government of Australia’s National Health and 
Medical Research Council; Instituto de Salud Carlos III (Ministerio de Sanidad y Consumo), Spain; British Heart 
Foundation; AstraZeneca.
Introduction
Worldwide, about 100 million adults undergo non-cardiac 
surgery every year.1 Non-cardiac surgery is associated 
with major cardiovascular complications and over 
1 million patients are likely to have such a complication 
every year.2
Non-cardiac surgery causes a rise in catecholamine 
concentrations that results in an increase in heart rate, 
blood pressure, and free fatty acid concentrations, which 
in turn increases myocardial oxygen demand.2–4 β blockers 
attenuate the eﬀ ects of increased catecholamine levels 
and therefore could prevent perioperative cardiovascular 
complications.5,6 Small non-cardiac surgery trials 
suggested that β blockers might reduce the occurrence of 
major cardiovascular events,7,8 although these trials had 
methodological limitations.9 Recent, moderate sized 
randomised controlled trials of perioperative β blockers 
did not demonstrate beneﬁ t.10,11 A meta-analysis of 
non-cardiac surgery randomised controlled trials 
suggested that β blockers might prevent major 
cardiovascular events but increase the risk of hypotension 
and bradycardia.12 To further investigate the eﬀ ects of 
perioperative β-blocker therapy, we undertook the 
PeriOperative ISchemic Evaluation (POISE) trial, a 
randomised controlled trial comparing the eﬀ ect of 
extended-release metoprolol succinate with that of 
placebo on 30-day risk of major cardiovascular events in 
patients with, or at risk of, atherosclerotic disease who 
were undergoing non-cardiac surgery.
Methods
Patients
Recruitment for POISE took place between October, 2002, 
and July, 2007. Patients were eligible if they were 
undergoing non-cardiac surgery, were aged 45 years or 
older, had an expected length of hospital stay of at least 
24 h, and fulﬁ lled any one of the following criteria: history 
of coronary artery disease; peripheral vascular disease; 
stroke; hospitalisation for congestive heart failure within 
previous 3 years; undergoing major vascular surgery (ie, 
vascular surgery except arteriovenous shunt, vein 
stripping procedures, and carotid endarterectomies); or 
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any three of seven risk criteria (undergoing intrathoracic 
or intraperitoneal surgery, history of congestive heart 
failure, transient ischaemic attack, diabetes, serum 
creatinine >175 µmol/L, age >70 years, or undergoing 
emergent or urgent surgery).
Patients meeting any of the following criteria were 
excluded: heart rate under 50 beats per minute (bpm); 
second or third degree heart block; asthma; receiving a 
β blocker or their physician planned to start one 
perioperatively; prior adverse reaction to a β blocker; 
coronary artery bypass graft surgery in the preceding 
5 years and no cardiac ischaemia since; low-risk surgical 
procedure (based on individual physician’s judgment); 
on verapamil; or previous enrolment in POISE.
All participating sites obtained ethical approval from 
institution ethics review boards before recruiting patients. 
All participants provided written informed consent.
Procedures
Details of the methods of this trial have been published 
previously.13 Brieﬂ y, after obtaining written informed 
consent, patients were randomly assigned to treatment 
group via a 24-h computerised randomisation phone 
service using block randomisation stratiﬁ ed by centre. 
Participants, health-care providers, data collectors, and 
outcome adjudicators were masked to treatment 
allocation but data analysts were not.
The study regimen was inﬂ uenced by practicality (eg, 
starting the study drug 2–4 h before surgery) and trials 
that showed that extended-release metoprolol 200 mg 
daily had a more even reduction in exercise heart rate 
and systolic blood pressure than did atenolol 100 mg 
daily14 and better anti-anginal eﬀ ects than metoprolol 
100 mg twice daily.15 Furthermore, the operations 
committee reviewed conﬁ dential blinded safety data on 
the ﬁ rst 10 000 patients included in COMMIT (a 
randomised controlled trial of 45 852 patients with acute 
myocardial infarction randomised to early intravenous 
metoprolol and starting on day 2 extended-release 
metoprolol 200 mg daily vs placebo).16
In POISE, patients received the ﬁ rst dose of the study 
drug (ie, oral extended-release metoprolol 100 mg or 
matching placebo) 2–4 h before surgery. Study drug 
administration required a heart rate of 50 bpm or more 
and a systolic blood pressure of 100 mm Hg or greater; 
these haemodynamics were checked before each 
administration. If, at any time during the ﬁ rst 6 h after 
surgery, heart rate was 80 bpm or more and systolic blood 
pressure was 100 mm Hg or higher, patients received 
their ﬁ rst postoperative dose (extended-release metoprolol 
100 mg or matched placebo) orally. If the study drug was 
not given during the ﬁ rst 6 h, patients received their ﬁ rst 
postoperative dose at 6 h after surgery. 12 h after the ﬁ rst 
postoperative dose, patients started taking oral 
extended-release metoprolol 200 mg or placebo every day 
for 30 days. If a patient’s heart rate was consistently 
below 45 bpm or their systolic blood pressure dropped 
below 100 mm Hg, study drug was withheld until their 
heart rate or systolic blood pressure recovered; the study 
drug was then restarted at 100 mg once daily. Patients 
whose heart rate was consistently 45–49 bpm and systolic 
blood pressure exceeded 100 mm Hg delayed taking the 
study drug for 12 h.
Patients who were unable to take medications orally 
received the study drug by slow or rapid intravenous 
infusion every 6 h until they could resume oral 
medications. The slow infusion consisted of 15 mg of the 
study drug in 25 mL normal saline infused over 60 min; 
heart rates and blood pressures were checked at 10, 30, 
and 60 min into the infusion. If a patient’s heart rate 
dropped below 50 bpm or systolic blood pressure dropped 
to below 100 mm Hg the infusion was stopped and 
subsequent infusions had 10 mg of study drug. The rapid 
intravenous infusion consisted of 5 mg of the study drug 
infused over 2 min and repeated—as long as 
haemodynamic criteria were met—every 5 min for a total 
of 15 mg. Investigators were allowed to select either the 
slow or rapid intravenous infusion for any participant 
who was unable to take medications orally.
An electrocardiograph (ECG) was recorded 6–12 h 
postoperatively and on the ﬁ rst, second, and 30th days 
after surgery. We obtained a measurement of troponin or, 
if unavailable, a creatine kinase-MB measurement 6–12 h 
postoperatively and on the ﬁ rst, second, and third days 
after surgery. These measurements were recorded on the 
case report forms and forwarded to the POISE project 
oﬃ  ce. All measurements were reviewed centrally. If a 
patient’s biomarkers or cardiac enzymes were raised but 
a myocardial infarction case report form was not 
submitted, we asked the centre to review the case to 
ensure that a myocardial infarction was not missed. 
Centres were encouraged to obtain more frequent ECGs 
9298 randomised 
8 lost to follow-up 12 lost to follow-up 
474 excluded because of
         fraudulent data  
473 excluded because of
         fraudulent data  
4648 allocated extended- 
            release metoprolol
4650 allocated placebo 
4174 allocated metoprolol
            included in trial  
  4174 patients analysed by
              intention to treat
(4166 patients with
             complete 30-day
             follow-up data)
4177 allocated placebo
           included in trial  
  4177 patients analysed by
             intention to treat
(4165 patients with
            complete 30-day
            follow-up data)
Figure 1: Trial proﬁ le
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and cardiac biomarkers if they suspected a myocardial 
infarction.
The prespeciﬁ ed primary outcome was a composite of 
cardiovascular death, non-fatal myocardial infarction, 
and non-fatal cardiac arrest at 30 days after randomisation. 
Individual secondary outcomes at 30 days are shown in 
webtable 1. Outcome adjudicators—clinicians blinded to 
treatment allocation—adjudicated whether a death was 
cardiovascular or non-cardiovascular, and whether a 
patient had a myocardial infarction, non-fatal cardiac 
arrest, or stroke; their decisions were used in the 
statistical analyses.
Monitoring in POISE consisted of central data 
consistency checks, statistical monitoring, and on-site 
monitoring. On-site monitoring occurred at all hospitals 
that recruited 40 or more participants and all sites that 
stood out on statistical monitoring. For the on-site 
monitoring, the study statistician randomly selected 
participants with and without primary outcome events 
and independent monitors audited their hospital charts 
and all other supporting documents. The 560 POISE 
participants for whom on-site monitoring occurred came 
from 77 hospitals that collectively randomised 85% of all 
trial participants; 88% of the primary outcomes occurred 
at these hospitals. On-site monitoring, outside of the 
special cases reported in webappendix 1, did not indicate 
any major discrepancies between the submitted data and 
the audit ﬁ ndings.
Statistical analysis
Assuming an event rate in the control group of 6% for our 
primary outcome, we calculated that 8000 randomised 
patients would provide 85% power and 10 000 patients 
92% power to detect a relative risk reduction of 25% 
(two-sided α=0·05).13 We set a goal to randomise 
10 000 patients, recognising that we would have adequate 
power if we randomised 8000 patients.13 Without knowledge 
of the trial results and knowing that we had randomised 
more than 8000 patients and had a higher than predicted 
event rate, the operations committee decided to terminate 
recruitment on July 31, 2007, mainly because the remaining 
study drug expired in September, 2007.
We analysed patients in the treatment group to which 
they were allocated—ie, on an intention-to-treat basis. 
Patients lost to follow-up without having the outcome 
of interest were censored on the last day their outcome 
status was known. All analyses used Cox proportional 
hazards models except for new clinically signiﬁ cant 
atrial ﬁ brillation, cardiac revascularisation, congestive 
heart failure, clinically signiﬁ cant hypotension, and 
clinically signiﬁ cant bradycardia, for which we used a 
χ² test.
On the basis of a study that suggested perioperative 
β-blocker eﬃ  cacy might vary across baseline risk,17 we 
prespeciﬁ ed our primary subgroup analysis on the basis 
of the revised cardiac risk index scoring system.18 We also 
did prespeciﬁ ed secondary subgroup analyses based on 
sex, type of surgery, and use of an epidural or spinal 
anaesthetic. For all subgroup analyses, we used Cox 
proportional hazard models that incorporated tests for 
interactions, designated to be signiﬁ cant at p<0·05.
Metoprolol group 
(N=4174)
Placebo group
(N=4177)
Age (years) 68·9 (10·5) 69·1 (10·4)
Sex (female) 1549 (37·1%) 1509 (36·1%)
Preoperative heart rate (beats per minute) 77·6 (12·2) 78·1 (12·4)
Preoperative blood pressure (mm Hg) 138·7 (19·9)/78·3 (11·3) 138·7 (19·7)/78·5 (11·3)
Patients fulﬁ lling eligibility criteria
Coronary artery disease 1805 (43·3%) 1784 (42·7%)
Peripheral arterial disease 1731 (41·5%) 1680 (40·2%)
Stroke thought due to atherothrombotic disease 619 (14·8%) 644 (15·4%)
Hospitalisation for CHF within 3 years of 
randomisation
112 (2·7%) 108 (2·6%)
Undergoing major vascular surgery 1500 (36·0%) 1485 (35·6%)
Three of seven risk factors 765 (18·3%) 788 (18·9%)
Intrathoracic or intraperitoneal surgery 997 (23·9%) 1026 (24·6%)
Any history of congestive heart failure 260 (6·2%) 239 (5·7%)
Diabetes and currently on an oral hypoglycaemic 
agent or insulin
1217 (29·2%) 1210 (29·0%)
Preoperative serum creatinine >175 µmol/L 207 (5·0%) 194 (4·6%)
Age >70 years 2106 (50·5%) 2205 (52·8%)
History of a transient ischaemic attack 442 (10·6%) 440 (10·5%)
Emergent/urgent surgery 440 (10·5%) 438 (10·5%)
Other cardiovascular risk factors
History of hypertension 2635 (63·2%) 2627 (62·9%)
Current smoker 806 (19·3%) 793 (19·0%)
Pre-operative cardiac medications*
Aspirin 1517 (36·4%) 1494 (35·8%)
Low-molecular weight heparin or intravenous 
unfractionated heparin
388 (9·3%) 384 (9·2%)
ACE inhibitor or ARB 1849 (44·3%) 1868 (44·7%)
Statin 1335 (32·0%) 1342 (32·1%)
Diuretic 912 (21·9%) 852 (20·4%)
Calcium channel blocker 902 (21·6%) 937 (22·4%)
Surgery
Vascular 1749 (41·9%) 1716 (41·1%)
Intraperitoneal 887 (21·3%) 928 (22·2%)
Orthopaedic 873 (20·9%) 883 (21·1%)
Other 665 (15·9%) 650 (15·6%)
Anaesthesia/analgesia
General 1965 (47·1%) 1985 (47·5%)
Spinal 717 (17·2%) 696 (16·7%)
Lumbar epidural 460 (11·0%) 441 (10·6%)
General and thoracic epidural 377 (9·0%) 351 (8·4%)
General and lumbar epidural 140 (3·4%) 155 (3·7%)
Regional anaesthesia 139 (3·3%) 145 (3·5%)
Other 322 (7·7%) 333 (8·0%)
Data are mean (SD) or n (%).  ACE=angiotensin-converting enzyme, ARB=angiotensin-receptor blocker. 
CHF=congestive heart failure. *Any use in 24 h before surgery except for aspirin which only required any use in the 
7 days before surgery.
Table 1: Preoperative characteristics and type of surgery and anaesthesia or analgesia
See Online for webtable 1 and 
webappendix 1
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The independent external safety, eﬃ  cacy, and 
monitoring committee planned to do three unblinded 
interim analyses and review adverse events after 
about 2500, 5000, and 7500 patients were randomised. 
The ﬁ rst two interim analyses were completed but the 
operations committee and safety, eﬃ  cacy, and monitoring 
committee jointly decided to forgo the third because the 
trial would complete recruitment shortly thereafter. For 
both interim analyses, the monitoring committee required 
surpassing of the following thresholds in at least two 
consecutive analyses 3 months or more apart before 
making a recommendation to consider stopping the trial: 
for the primary outcome, four standard deviations, and 
for an adverse eﬀ ect on mortality, three standard 
deviations of the hazard ratio.19,20 The α-level for the ﬁ nal 
analyses remained α=0·05 in view of the infrequent 
interim analyses, their extremely low α levels, and their 
requirement for conﬁ rmation with subsequent analyses. 
Statistical analyses were done with SAS version 9.1 for 
unix. Meta-analyses were done with Rev Man version 4.2.
Role of the funding source
The Population Health Research Institute, Hamilton 
Health Sciences, and McMaster University, Hamilton, 
Ontario, Canada coordinated the study, managed the 
data, and undertook analyses, under the supervision of 
the operations committee, who designed POISE. None 
of the funding sources had a role in the trial design, 
conduct, data collection, analyses, data interpretation, 
or writing of this manuscript. The sponsors were not 
involved in developing the analysis plan or in the 
analysis. The data analysis plan was prespeciﬁ ed by the 
operations committee, who vouch for the data and 
analyses. The corresponding author had full access to 
all data in the trial. The writing committee had ﬁ nal 
responsibility for the decision to submit for 
publication.
Results
Figure 1 shows the trial proﬁ le. Concern was raised 
during central data consistency checks about 
752 participants at six hospitals in Iran coordinated by 
one centre and 195 participants associated with one 
research assistant in three of 11 hospitals in Colombia. 
On-site auditing of these hospitals and cases indicated 
that fraudulent activity had occurred. Before the trial was 
concluded, the operations committee—blinded to the 
trial results at these hospitals and overall—decided to 
exclude these data (webappendix 1).
The analyses presented here thus focus on 8351 patients 
from 190 hospitals in 23 countries (ﬁ gure 1). The 30-day 
follow-up was complete for 8331 (99·8%) participants. 
Table 1 shows the preoperative characteristics, the type of 
surgery, and anesthaesia or analgesia used in the two 
groups. Atherosclerotic cardiovascular disease was 
common: 3444 [83%] patients in the metoprolol group 
and 3410 [82%] patients in the placebo group had a history 
of coronary artery disease, peripheral vascular disease, or 
stroke. During the 30-day follow-up period, we had to 
unblind patients or health-care providers to nine 
treatment allocations; in six of these cases unblinding 
occurred after the patient had experienced a primary 
outcome or a non-cardiovascular death. Table 2 shows 
adherence to study medications. Bradycardia or 
hypotension were the most common reasons for 
temporary discontinuations.
Signiﬁ cantly fewer participants in the metoprolol group 
than in the placebo group experienced the primary 
endpoint (hazard ratio 0·84, 95% CI 0·70–0·99, 
p=0·0399; table 3). This beneﬁ cial eﬀ ect resulted from 
fewer myocardial infarctions in the metoprolol group 
than in the placebo group (0·73, 0·60–0·89, p=0·0017; 
table 3). Figure 2 shows the Kaplan-Meier estimates for 
the primary outcome and for myocardial infarction, the 
curves of which separated during the ﬁ rst few days after 
surgery.
By contrast, more individuals in the metoprolol group 
than in the placebo group had a stroke (hazard ratio 2·17, 
95% CI 1·26–3·74, p=0·0053; table 3); the Kaplan-Meier 
estimates started separating on day 1 (ﬁ gure 2).Of the 
60 strokes that occurred in the metoprolol group, 
Metoprolol group (N=4174) Placebo group (N=4177)
Took 100% of study drug 2919 (70%) 3193 (76%)
Took >80% of study drug 3162 (76%) 3255 (78%)
Temporary discontinuation of study drug 752 (18%) 495 (12%)
Due to bradycardia or hypotension 555 (13%) 274 (7%)
Data are n (%).
Table 2: Adherence to study medication
Metoprolol 
group 
(n=4174)
Placebo 
group 
(n=4177)
Hazard ratio p value
Cardiovascular death, non-fatal myocardial 
infarction, or non-fatal cardiac arrest*
244 (5·8%) 290 (6·9%) 0·84 (0·70–0·99) 0·0399
Cardiovascular death 75 (1·8%) 58 (1·4%) 1·30 (0·92–1·83) 0·1368
Non-fatal myocardial infarction 152 (3·6%) 215 (5·1%) 0·70 (0·57–0·86) 0·0008
Non-fatal cardiac arrest 21 (0·5%) 19 (0·5%) 1·11 (0·60–2·06) 0·7436
Total mortality 129 (3·1%) 97 (2·3%) 1·33 (1·03–1·74) 0·0317
Myocardial infarction 176 (4·2%) 239 (5·7%) 0·73 (0·60–0·89) 0·0017
Cardiac revascularisation† 11 (0·3%) 27 (0·6%) 0·41 (0·20–0·82) 0·0123
Stroke 41 (1·0%) 19 (0·5%) 2·17 (1·26–3·74) 0·0053
Non-fatal stroke 27 (0·6%) 14 (0·3%) 1·94 (1·01–3·69) 0·0450
Congestive heart failure† 132 (3·2%) 116 (2·8%) 1·14 (0·89–1·46) 0·3005
New clinically signiﬁ cant atrial ﬁ brillation† 91 (2·2%) 120 (2·9%) 0·76 (0·58–0·99) 0·0435
Clinically signiﬁ cant hypotension† 625 (15·0%) 404 (9·7%) 1·55 (1·38–1·74) <0·0001
Clinically signiﬁ cant bradycardia† 277 (6·6%) 101 (2·4%) 2·74 (2·19–3·43) <0·0001
Non-cardiovascular death 54 (1·3%) 39 (0·9%) 1·39 (0·92–2·10) 0·1169
Data are n (%) or hazard ratio or relative risk (95% CI). *Some patients had more than one event. †Relative risks 
presented, rather than hazard ratios, since we did not collect the actual date patients experienced these events. 
Table 3: Eﬀ ects of study treatment on primary and secondary outcomes at 30 days
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49 were ischaemic and three were haemorrhagic; the 
type of stroke was designated uncertain for the 
remaining eight cases.
More people receiving metoprolol died than did 
individuals receiving placebo (1·33, 1·03–1·74, p=0·0317; 
table 3); the Kaplan-Meier estimates started separating 
on day 10 (ﬁ gure 2). Webtable 2 shows the causes of death 
as reported by investigators; the only reported cause of 
death for which there was a signiﬁ cant diﬀ erence between 
groups was sepsis or infection, which was more common 
among patients allocated to metoprolol.
Fewer patients in the metoprolol group than in the 
placebo group had a non-fatal myocardial infarction 
(hazard ratio 0·70, 95% CI 0·57–0·86; p=0·0008; table 3). 
More patients, however, had a non-fatal stroke in the 
metoprolol group than in the placebo group (1·94, 
1·01–3·69; p=0·0450; table 3). Less than half the 
patients who had a non-fatal myocardial infarction also 
had ischaemic symptoms (ie, chest, epigastric, arm, 
wrist, or jaw discomfort, shortness of breath; 
48 [31·6%] patients in the metoprolol group and 
82 [38·1%] in the placebo group). Less than a third of 
patients who had a non-fatal myocardial infarction also 
had congestive heart failure, coronary revascularisation, 
or went on to have a non-fatal cardiac arrest (table 4). 
Most patients who had a non-fatal stroke subsequently 
required help to perform everyday activities or were 
incapacitated (table 4).
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Figure 2: Kaplan-Meier estimates of the primary outcome (A), myocardial infarction (B), stroke (C), and death (D)
See Online for webtable 2
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Fewer individuals in the metoprolol group had cardiac 
revascularisation or developed new clinically signiﬁ cant 
atrial ﬁ brillation than did those in the placebo group, but 
more receiving metoprolol had clinically signiﬁ cant 
hypotension and bradycardia (table 3).
Median length of hospital stay was 8 (IQR 4–14) days in 
the metoprolol group and 8 (4–15) days in the placebo 
group (p=0·4046). The number of nights spent in an 
intensive or cardiac care unit was much the same in the 
two groups (0 nights: 71·1% in the metoprolol group vs 
71·4% in the placebo group; 1–2 nights: 18·7% vs 18·4%; 
3 nights or more: 10·2% vs 10·1%). At hospital discharge, 
participants who had received metoprolol had a lower 
mean heart rate than did placebo patients (71·6 [SD 12·0] 
vs 78·6 [11·8] bpm; p<0·0001); and patients in the 
metoprolol group had a lower mean systolic and diastolic 
blood pressure than did those in the placebo group 
(129·0 [18·9]/72·0 [11·1] vs 131·1 [18·2]/74·2 [11·1] 
mm Hg; p<0·0001 for both systolic and diastolic).
Figure 3 shows the results of our prespeciﬁ ed subgroup 
analyses and indicates consistency of eﬀ ects. Although 
not planned, based on our ﬁ ndings related to mortality, 
myocardial infarction, and stroke, we repeated the 
subgroups analyses in ﬁ gure 3 for these individual 
outcomes and also assessed whether there was a subgroup 
eﬀ ect based on region (ie, Asia; Europe, Australia, New 
Zealand; North America; South America), whether on-site 
monitoring occurred, and based on the presence of 
atherosclerotic cardiovascular disease. None of these 
analyses showed a subgroup eﬀ ect (data not shown). Our 
subgroup analyses were underpowered to detect the 
modest diﬀ erences in subgroup eﬀ ects that one might 
expect to detect if there was a true subgroup eﬀ ect. 
Post-hoc multivariable analyses to investigate how 
extended release metoprolol could have increased the risk 
of death and stroke are shown in table 5 and webappendix 2. 
Clinically signiﬁ cant hypotension had the largest 
population attributable risk for death and the largest 
intraoperative or postoperative risk for stroke.
Discussion
These data indicate that although perioperative 
extended-release metoprolol reduced the risk of 
myocardial infarction, cardiac revascularisation, and 
clinically signiﬁ cant atrial ﬁ brillation 30 days after 
randomisation compared with placebo, the drug also 
resulted in a signiﬁ cant excess risk of death, stroke, and 
clinically signiﬁ cant hypotension and bradycardia.
Although the exclusion of a number of randomised 
patients from our analyses because of fraudulent activities 
could be seen as a limitation, our on-site monitoring 
assessed the hospitals that collectively contributed 88% of 
the primary outcomes, and showed that the trial was 
rigorously done in all these hospitals. Further, subgroup 
analyses suggest there were no diﬀ erences in eﬀ ects 
across hospitals on the basis of whether or not on-site 
monitoring occurred. One should also note that all 
questionable data were excluded from all analyses, 
without knowledge of the results, when evidence of fraud 
was found. We disclosed this information to our external 
safety, eﬃ  cacy, and monitoring committee and to all 
relevant authorities.
We did a number of meta-analyses of trials of 
perioperative β blockers including events within a 30-day 
follow-up period. In a meta-analysis of eight trials, 
including POISE,6,8,10,11,21–23 β blockers did not show a 
signiﬁ cant eﬀ ect on death (ﬁ gure 4, webtable 3), but there 
was moderate heterogeneity that was explained by one 
Metoprolol 
group
Placebo 
group
Non-fatal myocardial infarction 152 215
Congestive heart failure† 30 (20%) 30 (14%)
Non-fatal cardiac arrest 7 (5%) 3 (1%)
Cardiac revascularisation† 9 (6%) 19 (9%)
Non-fatal stroke‡ 27 14
Full recovery 4 (15%) 3 (21%)
Persistent symptoms but no functional 
limitation
4 (15%) 1 (7%)
Functional impairment but patient can 
manage independently
4 (15%) 1 (7%)
Patient requires help to do everyday activities 8 (30%) 9 (64%)
Patient incapacitated 7 (26%) 0 (0%)
*If still alive 30 days after randomisation. †Actual date patients had these events 
not collection, therefore we cannot state with certainty if these events preceded 
the non-fatal myocardial infarction. ‡Outcome at 7 days or discharge, whichever 
was earlier, after stroke onset.
Table 4: Outcomes for patients with a non-fatal myocardial infarction 
and non-fatal stroke*
Number of cardiac risk factors
Sex
Surgery
Anaesthesia
0
1
2
3
4+
Men
Women
Vascular
Orthopaedic
Intraperitoneal
Other
Epidural/spinal
Other
Interaction p value
0·1524
0·9324
0·3463
0·6093
HR (95% CI)
Secondary subgroups
Primary subgroup
0·5 1·0 1·5 2·0
//
//
*
†
Figure 3: Subgroup analyses for the primary outcome
*Upper CI 2·51. †Upper CI 3·69.
See Online for webtable 3
See Online for webappendix 2
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trial with few events and an extreme result that led to early 
stopping.8 Exclusion of this trial from the meta-analysis 
suggests that the risk of death increases with β blockers 
(relative risk 1·29, 95% CI 1·02–1·62; p=0·03; I²=0%). By 
contrast, a meta-analysis of the nine trials, again including 
POISE, in which at least one patient had a non-fatal 
myocardial infarction8,10,11,22,24–27 suggests that β blockers 
reduce the risk of this outcome, but there was substantial 
heterogeneity. Analysis of the six trials, including POISE, 
that were blinded and not stopped early for an unexpected 
large treatment eﬀ ect with few events resulted in 
essentially the same estimate of eﬀ ect but no heterogeneity 
(0·73, 0·60–0·88; p=0·001; I²=0%).10,11,22,24,25 Patients in 
POISE and ﬁ ve other trials had a non-fatal stroke within a 
30-day follow-up period.6,10,11,22,23 Meta-analysis of these trials 
indicates that perioperative β blockers increase the risk of 
non-fatal stroke (2·19, 1·26–3·78; p=0·005; I²=0%).
Because the results of other trials with diﬀ erent doses 
or alternate β blockers are consistent with POISE, the 
eﬀ ects of this group of drugs are unlikely to diﬀ er across 
diﬀ erent dosing regimens. Nonetheless, another 
β blocker or dosing regimen could possibly achieve 
diﬀ erent results. Our results highlight the risk in 
assuming a perioperative β-blocker regimen has beneﬁ t 
without substantial harm before the availability of a 
large randomised controlled trial establishing such 
ﬁ ndings.
Our results suggest that for every 1000 patients with a 
similar risk proﬁ le undergoing non-cardiac surgery, 
extended-release metoprolol would prevent 15 patients 
from having a myocardial infarction, three from 
undergoing cardiac revascularisation, and seven from 
developing new clinically signiﬁ cant atrial ﬁ brillation. 
The results also suggest that extended-release metoprolol 
would result in an excess of eight deaths, ﬁ ve patients 
having a stroke, 53 experiencing clinically signiﬁ cant 
hypotension, and 42 experiencing clinically signiﬁ cant 
bradycardia for every 1000 treated.
Our post-hoc multivariate analyses suggest that 
clinically signiﬁ cant hypotension, bradycardia, and stroke 
explain how β blockers increased the risk of death in this 
trial. Sepsis or infection was the only cause of death that 
was signiﬁ cantly more common among patients in the 
metoprolol group than in those in the placebo group. 
The hypotension that β blockers caused could have 
predisposed patients to developing nosocomial 
infection.28,29 The prevention of tachycardia seen with 
β blockers could delay the recognition of sepsis and 
infection, therefore delaying treatment, which might 
increase the risk of death. Furthermore, patients receiving 
β-blocker therapy who develop sepsis or infection might 
not have the capacity to mount the required 
haemodynamic response to sustain life or allow adequate 
delivery of antibiotics to tissue. The same mechanism 
might explain how β blockers had no eﬀ ect on 30-day 
mortality but signiﬁ cantly increased death due to shock 
in the COMMIT trial.16
0·10 1 2 4 8 16
Total mortality
Pre-POISE
POISE
Total
Non-fatal myocardial infarction
Pre-POISE
POISE
Total
Non-fatal stroke
p=0·10, I2=37%
p<0·0001, I2=31%
p=0·005, I2=0%
Pre-POISE
POISE
Total
β blocker
33/1080
129/4174
162/5254
25/958
152/4174
177/5132
12/972
27/4174
39/5146
Control
36/1070
97/4177
133/5247
42/919
215/4177
257/5096
3/967
14/4177
17/5144
Relative risk (99% CI)
0·89 (0·49–1·64)
1·33 (0·95–1·87)
1·21 (0·90–1·63)
0·58 (0·32–1·06)
0·71 (0·54–0·92)
0·69 (0·54–0·87)
2·98 (0·74–12·0)
1·93 (0·83–4·50)
2·19 (1·06–4·50)
Relative risk (99% CI)
Figure 4: Meta-analysis of β-blocker trials in patients undergoing non-cardiac surgery
Adjusted odds 
ratio (95% CI)
Frequency of 
risk factor n (%)
PAR* (95% CI)
Death
Preoperative independent predictors
No use of statin in 24 h before surgery 1·73 (1·22–2·46) 5674 (67·9%) 33·7% (18·3–53·6)
Age ≥70 years 1·65 (1·20–2·26) 4387 (52·5%) 29·3% (16·2–47·0)
Emergent/urgent surgery 3·71 (2·68–5·14) 878 (10·5%) 24·4% (18·0–32·2)
Serum creatinine >175 µmol/L 2·67 (1·75–4·08) 401 (4·8%) 9·5% (5·4–16·0)
History of congestive heart failure 1·76 (1·14–2·72) 535 (6·4%) 6·0% (2·5–13·6)
Use of low-molecular-weight heparin in 
24 h before surgery
1·74 (1·14–2·68) 556 (6·7%) 5·9% (2·4–13·8)
Intraoperative and postoperative predictors
Clinically signiﬁ cant hypotension 4·97 (3·62–6·81) 1029 (12·3%) 37·3% (29·5–45·8)
Myocardial infarction without ischaemic 
symptoms
3·45 (2·20–5·41) 271 (3·3%) 10·6% (6·4–17·0) 
Signiﬁ cant bleeding 1·67 (1·14–2·44) 553 (6·6%) 9·4% (4·3–19·5)
Stroke 18·97 (9·93–36·25) 60 (0·7%) 8·0% (5·0–12·5)
Clinically signiﬁ cant bradycardia 2·13 (1·37–3·32) 351 (4·2%) 7·9% (3·9–15·3)
Myocardial infarction with ischaemic 
symptoms
3·31 (1·78–6·15) 144 (1·7%) 4·2% (1·9–9·2)
Total explained ·· ·· 85·5% (78·8–90·4)
Stroke
Preoperative independent predictors
History of stroke or transient ischaemic 
attack
2·80 (1·66–4·73) 1759 (21·1%) 30·5% (17·1–48·2)
Use of clopidogrel or ticlopidine in 24 h 
before surgery
3·12 (1·43–6·77) 330 (4·0%) 9·1% (3·2–23·2)
Intraoperative and postoperative predictors
Clinically signiﬁ cant hypotension 2·14 (1·15–3·96) 1029 (12·3%) 14·7% (5·2–35·4)
Signiﬁ cant bleeding 2·18 (1·06–4·49) 553 (6·6%) 10·1% (3·0–28·5)
New clinically signiﬁ cant atrial ﬁ brillation 3·51 (1·45–8·52) 200 (2·4%) 6·9% (2·1–20·4)
Total explained ·· ·· 51·8% (37·1–66·2)
PAR=population attributable risk. *Proportion of all outcomes attributable to the relevant risk factor if causality were 
proven. We calculated PAR from a multivariate logisitic regression analysis and PAR estimates were calculated with 
IRAP (US National Cancer Institute, 2002).1
Table 5: Independent predictors of death and stroke and their associated population attributable risks
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The results of POISE and of our meta-analysis provide 
evidence that perioperative β blockers prevent non-fatal 
myocardial infarctions but increase the risk of non-fatal 
stroke. The consistency of the myocardial infarction and 
stroke results in the meta-analyses increases the 
plausibility of these ﬁ ndings. Our post-hoc multivariate 
analyses suggest that hypotension is a potential 
mechanism through which β blockers could increase the 
risk of stroke; however, identiﬁ ed risk factors explain 
only half of the strokes.
After 7 days, or at hospital discharge, most patients 
who had a non-fatal stroke were left requiring help to do 
everyday activities or were incapacitated. By contrast, few 
patients who had a non-fatal myocardial infarction had 
ischaemic symptoms, probably because most myocardial 
infarctions occurred during the ﬁ rst few days after 
surgery when patients were receiving analgesic 
medication.30 Furthermore, only a few patients who had 
a non-fatal myocardial infarction also had congestive 
heart failure, non-fatal cardiac arrest, or cardiac 
revascularisation.
For every 15 patients who participated in POISE, one 
had a cardiovascular death, non-fatal myocardial 
infarction, non-fatal cardiac arrest, or non-fatal stroke at 
30-day follow-up. In view of the large numbers of 
individuals undergoing surgery and the high risk of 
cardiovascular complications, more large trials are needed 
urgently. The results of this trial suggest that the addition 
of perioperative extended-release metoprolol has potential 
beneﬁ ts and risks. Patients who would place three times 
more value on avoiding a perioperative stroke than on 
avoiding a myocardial infarction, or who are unwilling to 
accept a probable increase in mortality, are unlikely to 
want perioperative extended-release metoprolol. Current 
perioperative guidelines that recommend β-blocker 
therapy to patients undergoing non-cardiac surgery 
should reconsider their recommendations in light of 
these ﬁ ndings.
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